Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00998829
First received: October 20, 2009
Last updated: November 28, 2012
Last verified: November 2012

October 20, 2009
November 28, 2012
May 2010
May 2012   (final data collection date for primary outcome measure)
  • To evaluate the prevalence of undiagnosed psoriatic arthritis in patients presenting with plaque psoriasis using the PASE (Psoriatic Arthritis Screening and Evaluation) questionnaire based on a score of ≥ 44 on the questionnaire [ Time Frame: 14 days ] [ Designated as safety issue: No ]
  • Evaluate the positive predictive value between PASE (Psoriatic Arthritis Screening and Evaluation) score ≥ 44 and rheumatologist-confirmed diagnosis of psoriatic arthritis in a population of tertiary Australian psoriasis patients [ Time Frame: 14 days ] [ Designated as safety issue: No ]
Prevalence of undiagnosed psoriatic arthritis in patients presenting with plaque psoriasis [ Time Frame: 14 days ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00998829 on ClinicalTrials.gov Archive Site
  • Evaluate the proportion of patients within the enrolled patient population with moderate-to-severe plaque psoriasis (PASI [Psoriasis Area and Severity Index] > 10) [ Time Frame: 1 day ] [ Designated as safety issue: No ]
  • Evaluate the proportion of patients in a tertiary population with moderate-to-severe psoriasis with respect to treatment history and current treatment [ Time Frame: 1 day ] [ Designated as safety issue: No ]
  • Describe quality of life (QoL) in a tertiary psoriasis patient population [ Time Frame: 1 day ] [ Designated as safety issue: No ]
  • Explore the relationship between disease severity and QoL (quality of life) and stratified by the presence or absence of psoriatic arthritis in a tertiary population [ Time Frame: 14 days ] [ Designated as safety issue: No ]
Evaluate the relationship between PASE score and rheumatologist-confirmed diagnosis of PsA [ Time Frame: 14 days ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis
An Australian Cross-Sectional Epidemiological Study To Evaluate The Prevalence Of Undiagnosed Psoriatic Arthritis In Psoriasis Patients In Dermatology Practice Focusing On Disease Severity, Disease Burden And Quality Of Life

This study aims to collect Australian data on the prevalence of undiagnosed psoriatic arthritis in patients with plaque psoriasis. In addition the study will assess disease severity and quality of life in Australian patients with psoriasis attending specialist dermatology clinics.

Consecutive psoriasis patients seen at each site will be invited to participate in the study

Observational
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Probability Sample

Specialist dermatology clinics

  • Arthritis, Psoriatic
  • Psoriasis
Other: questionnaire
There is no therapeutic intervention in this study. However PASE (Psoriatic Arthritis Screening and Evaluation) and other patient questionnaires will be completed by participants.
Study population
The group comprises the entire study population
Intervention: Other: questionnaire
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
458
May 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of plaque psoriasis
  • >= 18 years of age
  • Able to complete English-language questionnaires

Exclusion Criteria:

  • Participation in an interventional clinical trial in previous 3 months
  • Known rheumatologist-confirmed psoriatic arthritis
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Australia
 
NCT00998829
0881A6-4611, B1801063
No
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP